Primary Care Diabetes
Volume 5, Issue 4 , Pages 231-239 , December 2011

PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus—Study design

  • Clare Bradley

      Affiliations

    • Department of Psychology, Royal Holloway, University of London, Egham, Surrey, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0)1784 443708/3714; fax: +44 (0)1784 471168.
    • ,
  • Pedro de Pablos-Velasco

      Affiliations

    • Department of Endocrinology and Metabolism, Dr Negrin Hospital, Las Palmas University, Las Palmas de Gran Canaria, Spain
    • ,
  • Klaus G. Parhofer

      Affiliations

    • Medical Department II Grosshadern, Division of Endocrinology and Metabolism, Klinikum der Universität München, München, Germany
    • ,
  • Eveline Eschwège

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale, Université Paris XI, Villejuif, France
    • ,
  • Linda Gönder-Frederick

      Affiliations

    • Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, VA, USA
    • ,
  • Dominique Simon

      Affiliations

    • CESP, INSERM U-1018 Villejuif and Service de Diabétologie, Hôpital de la Pitié, Université Paris VI, Paris, France

Received 18 November 2010 ,Revised 20 April 2011 ,Accepted 26 April 2011.

References 

  1. International Diabetes Federation . Diabetes The Policy Puzzle: Is Europe Making Progress?. 2nd ed.. 2008;
  2. Shaw JE, Sicree RA, Zimmet PZ. Global prevalence of diabetes: estimates for the year 2010 and projections for 2030. Diabetes Res. Clin. Pract. 2010;87:4–14
  3. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 1997;14(Suppl. 5):S1–S85
  4. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–S12
  5. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2007;28:88–136
  6. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  7. American Diabetes Association . Executive summary: standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl. 1):S6–S12
  8. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 2007;147:386–399
  9. Goldberg RB, Holman R, Drucker DJ. Clinical decisions. Management of type 2 diabetes. N. Engl. J. Med. 2008;358:293–297
  10. Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia. 2002;45:S18–S22
  11. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia. 2002;45:S23–S28
  12. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545–2559
  13. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560–2572
  14. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360:129–139
  15. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772
  16. UK Prospective Diabetes Study (UKPDS) Group . Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 2009;22:1125–1136
  17. Sullivan MD, Anderson RT, Aron D, et al. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am. J. Cardiol. 2007;99:90i–102i
  18. Glasziou P, Alexander J, Beller E, Clarke P. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual. Life Outcomes. 2007;5:21
  19. Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of percieved impact of diabetes on quality of life: the ADDQoL. Qual. Life Res. 1999;8:79–91
  20. Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in Type 2 diabetes patients. Qual. Life Res. 2007;16:165–177
  21. Bradley C, Gilbride CJ. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes. Metab. 2008;10(Suppl. 2):50–65
  22. Mosnier-Pudar H, Hochberg G, Eschwege E, et al. How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey. Diabetes Metab. 2009;35:220–227
  23. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679
  24. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet. Med. 2005;22:1379–1385
  25. Peyrot M, Rubin RR, Lauritzen T, et al. Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study. Diabetologia. 2006;49:279–288
  26. Grandy S, Fox FM. EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Health Qual. Life Outcomes. 2008;6:18
  27. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med. Decis. Making. 2002;22:340–349
  28. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab. Res. Rev. 2002;18(Suppl. 3):S64–S69
  29. Wee HL, Tan CE, Goh SY, Li SC. Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) questionnaire in patients with diabetes in a multi-ethnic Asian country. Pharmacoeconomics. 2006;24:673–682
  30. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet. Med. 1994;11:510–516
  31. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet. Med. 1990;7:445–451
  32. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617–621
  33. Irvine A, Cox D, Gonder-Frederick L. The fear of Hypoglycaemia scale. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. 1994;pp. 133–155
  34. Collins MM, O'Sullivan T, Harkins V, Perry IJ. Quality of life and quality of care in patients with diabetes experiencing different models of care. Diabetes Care. 2009;32:603–605
  35. Biderman A, Noffb E, Harris SB, et al. Treatment satisfaction of diabetic patients: what are the contributing factors?. Fam. Pract. 2009;26:102–108
  36. Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2009;19:45–53
  37. Nozaki T, Morita C, Matsubayashi S, et al. Relation between psychosocial variables and the glycemic control of patients with type 2 diabetes: a cross-sectional and prospective study. Biopsychosoc. Med. 2009;3:
  38. Bradley C. Importance of differentiating health status from quality of life. Lancet. 2001;357:7–8
  39. Monnier L, Colette C, Owens DR. Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?. Diabetes Metab. 2008;34:207–216
  40. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–1412
  41. Alvarez GF, Tofe PS, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes. Metab. 2008;10(Suppl. 1):25–32
  42. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073–1084
  43. Wilson M, Moore MP, Lunt H. Treatment satisfaction after commencement of insulin in Type 2 diabetes. Diabetes Res. Clin. Pract. 2004;66:263–267
  44. Jennings AM, Lewis KS, Murdoch S, et al. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care. 1991;14:738–744
  45. Jordan J, Cahn P, Goebel F, et al. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS. 2005;19:9–18
  46. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J. Gen. Intern. Med. 2010;25:284–290

☆ Results from PANORAMA were presented at the 46th Annual European Association for the Study of Diabetes (EASD) Meeting, 2010 September 20–24, Stockholm, Sweden; and generated considerable interest and further feedback which has partly guided subsequent data analyses [P. de Pablos-Velasco, C. Bradley, E. Eschwège, L. Gönder-Frederick, K. Parhofer, H. Vandenberghe, D. Simon, The PANORAMA pan-European study: glycaemic control and treatment patterns in patients with type 2 diabetes, Diabetologia 53 (Suppl. 1) (2010) 1–556 (abstract no. A-10-685); C. Bradley, E. Eschwège, P. de Pablos-Velasco, K. Parhofer, D. Simon, M. Tafalla, E. Pascual, L. Gönder-Frederick, The PANORAMA pan-European study: impact of severe and non-severe hypoglycaemia on quality of life and other patient-reported outcomes in patients with type 2 diabetes, Diabetologia 53 (Suppl. 1) (2010) 1–556 (abstract no. A-10-1900)].

☆☆ NB In any future translations of this paper the titles and acronyms of all questionnaires for evaluating patient-reported outcomes must remain in English, unless the copyright holder has provided the relevant translation resulting from the linguistic validation of the questionnaire.

PII: S1751-9918(11)00030-1

doi: 10.1016/j.pcd.2011.04.004

Primary Care Diabetes
Volume 5, Issue 4 , Pages 231-239 , December 2011

Article Tools